Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) — Market Cap & Net Worth
Market Cap & Net Worth: Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has a market capitalization of $9.19 Billion ($9.19 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2376 globally and #846 in its home market, demonstrating a 0.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arrowhead Pharmaceuticals Inc's stock price $74.81 by its total outstanding shares 139408632 (139.41 Million). Analyse ARWR operating cash flow to see how efficiently the company converts income to cash.
Arrowhead Pharmaceuticals Inc Market Cap History: 2015 to 2026
Arrowhead Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $857.36 Million to $10.43 Billion (28.67% CAGR).
Index Memberships
Arrowhead Pharmaceuticals Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.38% | #46 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.02% | #267 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.55% | #31 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.54 Trillion | 0.12% | #11 of 602 |
Weight: Arrowhead Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arrowhead Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arrowhead Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.16x
Arrowhead Pharmaceuticals Inc's market cap is 11.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $216.08 Million | $158.33K | -$81.72 Million | 1364.74x | N/A |
| 2017 | $513.02 Million | $31.41 Million | -$34.38 Million | 16.33x | N/A |
| 2018 | $1.73 Billion | $16.14 Million | -$54.45 Million | 107.26x | N/A |
| 2019 | $8.84 Billion | $168.80 Million | $67.97 Million | 52.39x | 130.09x |
| 2020 | $10.70 Billion | $87.99 Million | -$84.55 Million | 121.57x | N/A |
| 2021 | $9.24 Billion | $138.29 Million | -$140.85 Million | 66.84x | N/A |
| 2022 | $5.65 Billion | $243.23 Million | -$176.49 Million | 23.25x | N/A |
| 2023 | $4.27 Billion | $240.74 Million | -$205.28 Million | 17.72x | N/A |
| 2024 | $2.62 Billion | $3.55 Million | -$599.49 Million | 738.07x | N/A |
| 2025 | $9.26 Billion | $829.45 Million | -$1.63 Million | 11.16x | N/A |
Competitor Companies of ARWR by Market Capitalization
Companies near Arrowhead Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Arrowhead Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Arrowhead Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Arrowhead Pharmaceuticals Inc's market cap moved from $857.36 Million to $ 10.43 Billion, with a yearly change of 28.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.43 Billion | +12.68% |
| 2025 | $9.26 Billion | +253.14% |
| 2024 | $2.62 Billion | -38.56% |
| 2023 | $4.27 Billion | -24.56% |
| 2022 | $5.65 Billion | -38.82% |
| 2021 | $9.24 Billion | -13.59% |
| 2020 | $10.70 Billion | +20.97% |
| 2019 | $8.84 Billion | +410.71% |
| 2018 | $1.73 Billion | +237.50% |
| 2017 | $513.02 Million | +137.42% |
| 2016 | $216.08 Million | -74.80% |
| 2015 | $857.36 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Arrowhead Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.19 Billion USD |
| MoneyControl | $9.19 Billion USD |
| MarketWatch | $9.19 Billion USD |
| marketcap.company | $9.19 Billion USD |
| Reuters | $9.19 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more